&Partners Grows Stake in Johnson & Johnson (NYSE:JNJ)

&Partners lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 260.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 114,986 shares of the company’s stock after acquiring an additional 83,044 shares during the quarter. Johnson & Johnson makes up 0.7% of &Partners’ portfolio, making the stock its 17th biggest position. &Partners’ holdings in Johnson & Johnson were worth $16,799,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Christopher J. Hasenberg Inc purchased a new position in Johnson & Johnson in the 1st quarter worth approximately $31,000. WFA Asset Management Corp increased its holdings in shares of Johnson & Johnson by 61.4% in the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 97 shares in the last quarter. MFA Wealth Advisors LLC purchased a new position in shares of Johnson & Johnson in the second quarter worth $43,000. Vermillion & White Wealth Management Group LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at $44,000. Finally, Disciplined Equity Management Inc. bought a new stake in Johnson & Johnson in the 4th quarter worth about $45,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Monday, August 5th. Daiwa Capital Markets downgraded shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Sanford C. Bernstein increased their price target on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. TD Securities cut their price objective on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a research report on Tuesday, July 30th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $173.21.

Johnson & Johnson Price Performance

NYSE JNJ opened at $164.10 on Friday. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $167.78. The stock has a market cap of $394.94 billion, a price-to-earnings ratio of 10.23, a PEG ratio of 2.63 and a beta of 0.52. The company’s 50 day moving average is $153.92 and its two-hundred day moving average is $153.27.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating the consensus estimate of $2.71 by $0.11. The firm had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company’s revenue was up 4.3% on a year-over-year basis. During the same period last year, the firm earned $2.80 EPS. As a group, research analysts anticipate that Johnson & Johnson will post 10.07 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.02%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.